GO
Loading...

Enter multiple symbols separated by commas

Isis Pharmaceuticals Inc

More

  • NEW YORK, June 19- The Russell 2000 index of small company stocks will lose some heavy hitters from the healthcare sector when FTSE Russell rebalances its indexes at the end of the month, depriving the index of companies that provided much of its growth this year. Stocks in the sector that are expected to be promoted to the larger cap index include Isis...

  • May 27- Drug developer GlobeImmune Inc said its experimental hepatitis B drug did not reduce infection in patients after 24 weeks of treatment in a mid-stage study, sending the company's shares down as much as 60 percent to a record low. GlobeImmune, which is developing the drug with Gilead Sciences Inc, is among several drugmakers looking to tap the demand for...

  • May 27- GlobeImmune Inc said its experimental hepatitis B drug did not meet the main goal of reducing infection in patients after 24 weeks, in a mid-stage trial. GlobeImmune is developing the drug, GS-4774, with Gilead Sciences Inc.. Companies developing hepatitis B drugs include Arrowhead Research Corp, Canada's Tekmira Pharmaceuticals Corp and Isis...

  • Cramer Remix: The selloff was made for this stock Wednesday, 25 Mar 2015 | 7:02 PM ET
    Jim Cramer on Mad Money.

    “Mad Money” host Jim Cramer is focusing on selloff wishes and portfolio dreams.

  • Lightning Round: The downgrade was wrong on this Monday, 16 Mar 2015 | 7:00 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer: This X factor is ignored in your portfolio Thursday, 5 Mar 2015 | 6:13 PM ET
    A Costco store in Alhambra, Calif.

    Jim Cramer sees one portfolio x factor that could change your stock perspective from overvalued to underestimated.

  • Arrowhead buys Novartis' RNAi portfolio Thursday, 5 Mar 2015 | 7:34 AM ET

    March 5- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins. Novartis is eligible to receive $25 million in Arrowhead shares within 30 days, which would make it the second-largest shareholder based on Arrowhead's market value on Wednesday.

  • Cramer's guide to the best stocks in a bear market Wednesday, 4 Mar 2015 | 6:34 PM ET
    Biotech

    Jim Cramer predicted bearish days ahead for March. But that doesn't mean you can't make money! Cramer gives his bear market survival guide of stocks.

  • Cramer Remix: Where's the Nasdaq bubble? Monday, 23 Feb 2015 | 7:02 PM ET
    Jim Cramer on the set of Mad Money

    As Apple hits new highs, "Mad Money" host Jim Cramer is betting on it to lift the Nasdaq.

  • Lightning Round: Don't listen to this CEO Monday, 23 Feb 2015 | 6:50 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Lightning Round: It's part of a major revolution Thursday, 12 Feb 2015 | 7:19 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Lightning Round: Why you should buy Box again Thursday, 5 Feb 2015 | 7:48 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Tuesday's midday movers: Target, Lear, NYT & more Tuesday, 3 Feb 2015 | 1:01 PM ET
    NYSE New York Stock Exchange traders markets

    Take a look at some of Tuesday's midday movers:

  • Feb 3- Isis Pharmaceuticals Inc's experimental diabetes drug took a longer-than-expected 36 weeks to reduce blood sugar levels in patients with type 2 diabetes. Deutsche Bank's Alethia Young said the data looked less robust that some commonly prescribed treatments and Isis's own experimental glucagon receptor, ISIS-GCGR. Type 2 diabetes is a chronic...

  • Feb 3- Isis Pharmaceuticals Inc said its experimental diabetes drug was effective in reducing the body weight and blood sugar in patients with type 2 diabetes. The drug, ISIS-PTP1B, was tested against a placebo in a mid-stage study comprising 92 type 2 diabetes patients with uncontrolled blood sugar, despite treatment. Type 2 diabetes is a chronic condition...

  • Feb 3- Isis Pharmaceuticals Inc said its experimental diabetes drug was effective in reducing the body weight and blood sugar of patients with type 2 diabetes.

  • Lightning Round: What to do with McDonald's Wednesday, 28 Jan 2015 | 6:47 PM ET
    McDonald's

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Lightning Round: Wait on this rocket ship stock Tuesday, 13 Jan 2015 | 7:43 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer Remix: The MVPs of today’s market Tuesday, 13 Jan 2015 | 7:07 PM ET
    Jim Cramer on Mad Money.

    "Mad Money" host Jim Cramer on the CEOs coaching their companies to new highs.